Skip to content

Dyskeratosis Congenita Autosomal Dominant 3 C3151445

Published: July 22, 2026Updated: August 20, 2026

This telomere biology disorder causes abnormal skin findings, nail problems, and oral changes. Patients have increased risk of bone marrow failure and cancer. Treatment involves regular monitoring and supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q84.9
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Hematopoietic stem cell transplantation

Curative approach replacing defective bone marrow with healthy donor stem cells to restore normal hematopoiesis in patients with bone marrow failure, the primary life-threatening complication of dyskeratosis congenita.

surgical
3

Androgen therapy for cytopenias

Anabolic androgens such as oxymetholone or danazol may stimulate erythropoiesis and improve blood counts in patients with bone marrow failure who are not transplant candidates.

medication

Additional treatment options

Cancer surveillance program

Regular examinations and imaging for early detection of malignancies, particularly head and neck, anogenital, and skin cancers which occur at elevated rates in dyskeratosis congenita.

monitoring

Psychosocial support services

Mental health counseling and support addressing chronic disease burden, body image concerns from cutaneous manifestations, and quality of life impacts of this life-limiting condition.

psychological

Transfusion support

Red blood cell and platelet transfusions to manage symptomatic anemia and thrombocytopenia while awaiting transplant or when other treatments are contraindicated.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dyskeratosis Congenita Autosomal Dominant 3 C3151445?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dyskeratosis Congenita Autosomal Dominant 3 C3151445. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy